Clinical Investigation of the Freedom SOLO Stentless Heart Valve

Not Applicable

Completed

• Conditions: Heart Valve Diseases

• Registration Number: NCT00876525
• Lead Sponsor: Corcym S.r.l

Brief Summary

This is a trial to demonstrate the safety and effectiveness of the Freedom SOLO heart valve when used to replace a diseased or dysfunctional aortic valve or aortic valve prosthesis.

Detailed Description

Freedom SOLO study is a prospective, non-randomized, multicenter trial on the Freedom SOLOvalve implanted in patients requiring aortic valve replacement. The study was conducted at 18 centers in Europe.

The study was based on single sample hypothesis testing that allows comparison of observed morbid event rates to objective performance criteria (OPCs). Based on the guidelines established by the U.S. Food and Drug Administration (FDA), the minimum sample size for this study was 800 valve-years, which is the minimum amount of data needed to test against the OPC of 1.2 %/patient-year.

Study Timeline

• Study Start: 2009-03
• Study First Submitted: 2009-04-03
• Study First Submitted QC: 2009-04-03
• Study First Posted: 2009-04-06
• Primary Completion: 2013-12
• Study Completion: 2017-12
• Status Verified: 2024-03
• Last Update Submitted: 2024-03-05
• Last Update Posted: 2024-03-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 702

Inclusion Criteria

• The patient is male or female 18 years old or older.
• The patient is willing to sign the informed consent.
• The patient which preoperative evaluation indicated the need for native or prosthetic aortic valve replacement.
• Any patient amenable to aortic valve replacement with biological prosthesis should be enrolled in the study, even in conjunction with valve repair, coronary artery bypass grafting and other procedures.
• The patient is located in a geographic location that will enable the subject to return to the study site for all follow-up examinations (i.e. geographically stable).
• Patient will be available to the investigator(s) for postoperative follow-up beyond one year.

Exclusion Criteria

• The patient has preexisting valve prosthesis in the mitral, pulmonary or tricuspid position.
• The patient requires a double or triple valve replacement (a valve repair is not considered an exclusion criterion).
• The patient has a previously implanted SOLO valve, within the clinical study, that requires replacement.
• The patient has active endocarditis.
• The patient is or will be participating in a concomitant research study of an investigational product.
• The patient is a minor, intravenous drug user, alcohol abuser, prisoner, institutionalized, or is unable to give informed consent.
• The patient has a major or progressive non-cardiac disease that, in the investigator's experience, results in a life expectancy of less than 1 year, or the implant of the device produces an unacceptable increased risk to the patient.
• The patient is pregnant or lactating.
• Patients with congenital bicuspid aortic valve.
• Patients are known to be noncompliant or are unlikely to complete the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
The complication and survival rates for the Freedom SOLO stentless valve.	up to 5 year	Safety of the Freedom SOLO was evaluated based on the following adverse events related to cardiac valve replacement: valve thrombosis, thromboembolism, bleeding, anticoagulant-related bleeding, paravalvular leak, endocarditis, clinically significant hemolysis, nonstructural dysfunction, structural valve deterioration, reoperation, explant, and death.

Secondary Outcome Measures

Name	Time	Method
Hemodynamic performance of the Freedom SOLO stentless valve: transvalvular peak and mean pressure gradients	up to 5 year	Decrease of transvalvular peak and mean pressure gradients from preoperative to follow up
Hemodynamic performance of the Freedom SOLO stentless valve: cardiac output (CO) Clinically significant improvement in overall patient condition.	up to 5 year	Improvement of Cardiac Output
Hemodynamic performance of the Freedom SOLO stentless valve: regurgitation Clinically significant improvement in overall patient condition.	up to 5 year	Evaluation of regurgitation, location and severity
Preoperative and postoperative NYHA functional classifications	Preoperatively, after the procedure (1 week), 3-6 months, 12 months and annually thereafter	NYHA functional classification data is presented as the number and percentage of patients in each functional class.
Hemodynamic performance of the Freedom SOLO stentless valve: effective orifice area (EOA) in cm2 by transthoracic echocardiography	up to 5 year	Increase of effective orifice area (EOA) from preoperative to follow up
Hemodynamic performance of the Freedom SOLO stentless valve: cardiac index (CI) Clinically significant improvement in overall patient condition.	up to 5 year	Improvement of Cardiac Index
Hemodynamic performance of the Freedom SOLO stentless valve: EOA index (EOAI cm2/m2).	up to 5 year	Increase of effective orifice area index from preoperative to follow up.

Trial Locations

Locations (19)

Krankenhaus Hietzing; 🇦🇹 Wien, Austria

Medical University Vienna; 🇦🇹 Wien, Austria

St. Luc Hospital; 🇧🇪 Bruxelles, Belgium

University Hospital Gent; 🇧🇪 Gent, Belgium

Hôpital Pontchaillou - CHU; 🇫🇷 Rennes, France

Hôpital Trousseau - CHRU; 🇫🇷 Tours, France

Herz- und Gefäß-Klinik GmbH; 🇩🇪 Bad Neustadt An Der Saale, Germany

Charité Hospital; 🇩🇪 Berlin, Germany

Herzzentrum Dresden Universitätsklinik an der Technischen Universität Dresden; 🇩🇪 Dresden, Germany

Universitätsklinikum Erlangen, Klinik für Herzchirurgie; 🇩🇪 Erlangen, Germany

Scroll for more (9 remaining)